Metabolic pathway analysis of hyperuricaemia patients with hyperlipidaemia based on high-throughput mass spectrometry: a case‒control study

Lipids in Health and Disease

Research

Sha Zhang¹  Xiaodong Jia¹  Xue Wei¹  Rui Liu²  Lei Zhou³  Yuanning Mo³  Jing An³  Shixuan Liu³  Xiao Li³  Yushi Zhang³ 

[1] Tianjin Union Medical Center, Tianjin Medical University, 300070, Tianjin, China;Tianjin Union Medical Centre, 300121, Tianjin, China;Tianjin Yunjian Medical Technology Co., Ltd., Tianjin, China;

关键词: Hyperuricaemia;    Hyperlipidaemia;    Metabolomics;    Amino acid metabolism;    Fatty liver;    Chronic kidney disease;   

DOI  :  10.1186/s12944-022-01765-0

 received in 2022-09-05, accepted in 2022-12-25,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundBoth hyperuricaemia and hyperlipidaemia are common metabolic diseases that are closely related to each other, and both are independent risk factors for the development of a variety of diseases. HUA combined with hyperlipidaemia increases the risk of nonalcoholic fatty liver disease and coronary heart disease. This study aimed to investigate the relationship between HUA and hyperlipidaemia and study the metabolic pathway changes in patients with HUA associated with hyperlipidaemia using metabolomics.MethodsThis was a case‒control study. The prevalence of hyperlipidaemia in HUA patients in the physical examination population of Tianjin Union Medical Centre in 2018 was investigated. Metabolomics analysis was performed on 308 HUA patients and 100 normal controls using Orbitrap mass spectrometry. A further metabolomics study of 30 asymptomatic HUA patients, 30 HUA patients with hyperlipidaemia, and 30 age-and sex-matched healthy controls was conducted. Differential metabolites were obtained from the three groups by orthogonal partial least-squares discrimination analysis, and relevant metabolic pathways changes were analysed using MetaboAnalyst 5.0 software.ResultsThe prevalence of hyperlipidaemia in HUA patients was 69.3%. Metabolomic analysis found that compared with the control group, 33 differential metabolites, including arachidonic acid, alanine, aspartate, phenylalanine and tyrosine, were identified in asymptomatic HUA patients. Pathway analysis showed that these changes were mainly related to 3 metabolic pathways, including the alanine, aspartate and glutamate metabolism pathway. Thirty-eight differential metabolites, including linoleic acid, serine, glutamate, and tyrosine, were identified in HUA patients with hyperlipidaemia. Pathway analysis showed that they were mainly related to 7 metabolic pathways, including the linoleic acid metabolism pathway, phenylalanine, tyrosine and tryptophan biosynthesis pathway, and glycine, serine and threonine metabolism pathway.ConclusionsCompared to the general population, the HUA population had a higher incidence of hyperlipidaemia. HUA can cause hyperlipidaemia. by affecting the metabolic pathways of linoleic acid metabolism and alanine, aspartate and glutamate metabolism. Fatty liver is closely associated with changes in the biosynthesis pathway of pahenylalanine, tyrosine, and tryptophan in HUA patients with hyperlipidaemia. Changes in the glycine, serine and threonine metabolism pathway in HUA patients with hyperlipidaemia may lead to chronic kidney disease.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 4

Fig. 2

Fig. 1

Fig. 1

Fig. 4

Fig. 3

Fig. 1